Form 4 for REED REED'S, INC.
Accepted 2025-06-11 00:00:00 ET · period of report 2025-06-04 · accession 0001641172-25-014725 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-06-11 | 2025-06-04 | REED | Era Regenerative Medicine Ltd | 10% | P - Purchase | — | +1.08M | 28.21M | +4% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-04 | P | A | 1,075,269 | — | 28,214,789 | I See footnote | — | — | (F2) The purchase price per share was $0.93. (F3) Includes 232,108 shares of common stock issuable upon exercise of currently exercisable warrants. (F4) Era Regenerative Medicine Ltd.("ERM") holds all the shares in D&D. Dai Siqi, currently the sole director of ERM, has sole voting and dispositive power over the securities of the Registrant held directly by D&D. |